EIF4E and non-small cell lung carcinoma: For the first time, our studies indicated that Everolimus targeted mTORC1 to induce the loss of intracellular miR-7-5p for activating MNK/eIF4E axis, thus impairing the effect of Everolimus in NSCLC.